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方法：选取成年雄性 SD 大鼠 50 只，随机分为 4 组，脑积水组 25 只，假手




射。所有分组在造模后 3 周，均行 MRI 检查，根据脑室扩大程度将脑积水
组分为轻度、中度和重度 3 个亚组。收集所有实验大鼠脑脊液标本，处死动






（2）ELISA 结果提示脑积水组大鼠脑脊液中 IL-18 表达量较假手术组升高，
差异有统计学意义(P＜0.05)，Pearson 直线相关性分析提示 IL-18 表达量与脑
积水进展呈正相关。 
（3）RT-PCR 结果提示脑积水组 GFAP 和 AIF-1 基因表达较假手术组升高，




（5）Western Blot 结果提示脑积水组 GFAP 和 Iba-1 蛋白表达较假手术组升





















（2）RT-PCR 结果提示米诺环素治疗组 GFAP 和 AIF-1 基因表达量较阴性干
预组减少，差异有统计学意义(P＜0.05)。 































Object: This study attempted to investigate the relationship between reactive 
gliosis and neuroinflammation of rats with hydrocephalus and the efficacy of 
minocycline to reduce reactive gliosis and delay the development of 
hydrocephalus.  
 
Methods: Adult male Sprague-Dawley rats (250 ±10g) were randomly divided 
into 4 groups: hydrocephalic group (n=25), sham group (n=5), minocycline 
treatment group (n=10) and saline treatment group (n=10). A 30-μl sterile 
suspension of 3% kaolin was injected into the lateral ventricle of animals to 
construct hydrocephalus model. Sham group underwent the same procedure but 
received sterile saline injection instead of kaolin. In the minocycline treatment 
group and saline treatment group, model building was same as hydrocephalus 
group. Minocycline was administered to minocycline group from 1-week 
post-operation by intraperitoneal injection, while saline treatment group were 
injected with saline. The ventricular volume and Evan’s ratio were calculated by 
MRI at 3-week post-operation, and the hydrocephalus group was subdivided into 
mild group, moderate group and severe group according to the degree of 
ventricular dilatation. Then IL-18, GFAP，Iba-1 were detected by ELISA, 
RT-PCR, Immunohistochemistry and Western blot while correlation analysis was 
conducted at the same time. 
 
Results:  
1. Hydrocephalic group verse sham group 
（1）All rats with kaolin injection into the lateral ventricle successfully developed 
mild to severe hydrocephalus by MRI examination. 
















than in sham group,IL-18 concentrations increase were positively correlated with 
the severity of hydrocephalus. 
（3）RT-PCR revealed that the mRNA expression of the GFAP significantly(P＜
0.05) elevated in hydrocephalic brain . GFAP mRNA positively correlated with 
the severity of hydrocephalus, while the expression of AIF-1 showed no 
difference between the each model group. 
（4）Densely-packed reactive astrocytes and microglial cells were found 
frequently in periventricular area, cortex and hippocampus of the hydrocephalic 
animals. 
（5）GFAP and Iba-1 protein expression increased significantly(P＜0.05) in the 
model groups compared to saline controls. GFAP protein evaluation is more 
obvious in severe group than that of the mild group, while the expression of 
AIF-1 showed no difference between the each model group. 
 
2. Minocycline treatment group verse saline treatment group 
（1）Compared with the saline treatment group, the Ventricular volumes and 
Evan’s ratio of minocycline treatment group is smaller(P＜0.05). 
（2）The level of GFAP and AIF-1 mRNA are more obvious in saline treatment 
group than that of the minocycline treatment group(P＜0.05). 
（3）In hydrocephalic with minocycline group, GFAP protein and Iba-1 
expression are lower than saline treatment group(P＜0.05). 
 
Conclusions:  
1. Our results further demonstrated the efficiency and stability of our 
experimental hydrocephalic model and provide an opportunity to be widely used. 
2. Reactive gliosis and neuroinflammation continue to rise dramatically in 
experimental hydrocephalus and can be regarded as an important factor of 
hydrocephalus.    
3. Minocycline treatment can not reverse the development of hydrocephalus but 
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Abbreviations and Acronyms 
英文缩写 英文全称 中文名称 
GFAP Glial Fibrillary Acidic Protein 神经胶原纤维酸性蛋白 
AIF-1 Allograft Inflammatory Factor-1 同种异体移植炎症因子-1 
Iba-1 
Ionized calcium bindingadaptor 
molecule-1 
钙接头蛋白-1 
TNF-α Tumor nectosis factor-α 肿瘤坏死因子-α 
COX- 2 cyclooxygenase-2 环氧化酶2 
PGE2 prostaglandin E2 前列腺素E2 
MC minocycline 米诺环素 
MG microglia 小胶质细胞 
IL-18 Interleukin-18 白介素-18 
IFN-γ interferon -γ 干扰素γ  
CSF Cerebrospinal fluid 脑脊液 
Elisa Enzyme-linked immunosorbent 酶联免疫吸附测定法 
MRI Magnetic Resonance Imaging  磁共振成像 
RT-PCR 
Reverse-transcription polymerase chain 
reaction 
逆转录－多聚酶链反应 
mRNA messenger ribonucleic acid     信使核糖核酸 





















DAB Diaminobenzidine 二氨基联苯胺 
PBS Phosphate buffered solution  磷酸盐缓冲液 
CT   cycle threshold 循环阈值 
bp base pair 碱基对 
cDNA complimentary deoxyribonucleic acid 互补脱氧核糖核酸 
RT   reverse transcription 逆转录 
PCR polymerase chain reaction 多聚酶链反应 
Min minute         分钟 
S second 秒 
M Median  中位数 
kd    kilo-dalton 千道尔顿 
FBS fetal bovine serum 胎牛血清 
HRP horseradish peroxidase    辣根过氧化物酶 
ECM Extracellular matrix  基质金属蛋白 
TIMP 
Tissue inhibitor of matrix 
metalloproteinase 
基质金属蛋白酶抑制剂物 
VEGF,  vascular endothelial growth factor 血管内皮生长因子 
VEGFR2 
vascular endothelial growth factor 
receptor 2 
血管内皮生长因子受体2 
















GABA gamma-aminobutyric acid γ-氨基丁酸 
HGF hepatocyte growth factor 肝细胞生长因子 
DWI Diffusion tensor imaging  弥散张量成像 




































    一氧化氮和谷氨酸在维持正常脑血流、神经内分泌方面有重要作用。但在病
理状态下，过量生成的 NO 和谷氨酸却有细胞毒性作用。在实验性脑积水动物
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